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Background: Animal studies have demonstrated that functional immune responses, as determined by the levels of
CD4+ cell counts and anti-schistosome antibodies responses, determine the efficacy of praziquantel. Based on this
evidence, it has been hypothesised that the immunodeficiency effects of the human immunodeficiency virus (HIV)-1
infection may affect the efficacy of praziquantel in co-infected human hosts. Thus, the present study assessed the
efficacy of praziquantel by comparing parasitological cure rates and the reduction in infection intensity in HIV-1
seronegative individuals infected with S. mansoni and HIV-1 seropositive individuals co-infected with S. mansoni,
following treatment with a single oral dose of praziquantel.
Methods: This was a prospective longitudinal study which included, at baseline, 555 S. mansoni infected adults aged
21–55 years, who were either co-infected or not with HIV-1 and who lived in fishing villages along Lake Victoria in
Northwest Tanzania. These individuals were treated with a single oral dose of praziquantel (40 mg/kg) and, at 12 weeks,
single stool samples were obtained and examined for S. mansoni eggs using the Kato-Katz technique. Finger prick and
venous blood samples were collected for HIV-1 screening and CD4+ cell quantification.
Results: The parasitological cure rate did not differ significantly from the HIV-1 serostatus (P = 0.12): among the
co-infected individuals, the cure rate was 48.3% (14/29), and among the individuals infected only with S. mansoni, the cure
rate was 62.6% (329/526). The egg reduction rate did not vary with the HIV-1 serostatus (P = 0.22): 77.22% for HIV-1
seronegative and 75% for HIV-1 seropositive individuals. The level of CD4+ cell counts (median 228 cells/μL: range
202–380 cells) did not influence the cure rate (P = 0.23) or the reduction in the intensity of the infection (P = 0.37).
Conclusion: The HIV-1 infection per se or its moderate immunodeficiency effects, demonstrated by the range of CD4+ cell
counts observed in co-infected individuals, did not affect praziquantel efficacy, as measured by the parasitological cure
rate and the reduction in intensity of infection in the present study cohort.
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Background
The World Health Organization (WHO) recommends the
use of praziquantel for the treatment and morbidity con-
trol of schistosomiasis in endemic areas [1-3]. The drug
has minimal serious side effects, is easy to administer and
its price has been substantially reduced since its introduc-
tion [4-6]. Using a recommended single dose (40 mg/kg),
the parasitological cure rates of praziquantel for S. man-
soni ranges from 18% to 90% [7-11]. The reduction of the
infection intensity reportedly ranges from 80% to 95%,
when using the recommended single oral dose of 40 mg/
kg and as assessed between four and 12 weeks after treat-
ment [8,12,13].
The efficacy of praziquantel appears to depend on the
synergy with the host’s intact immunological response
against the adult worms [14-17]. Studies involving S. man-
soni animal models have demonstrated the immune-
dependent action of the drug, whereby immunodeficient
animal models have a reduced efficacy [14-17]. Pre-
immunisation of S. mansoni animals models with parasite
antigens to generate parasite-specific antibodies [18,19], or
the passive transfer of immune serum from immunocom-
petent animal models, increases praziquantel efficacy
[17,19,20]. This indicates that a functional and intact im-
mune response is required to enhance praziquantel effi-
cacy [19].
The demonstration that praziquantel efficacy is immune-
dependent in S. mansoni animal models [16,19,20] suggests
that human immunodeficiency virus (HIV)-1 associated
immunodeficiency may affect praziquantel efficacy in hu-
man populations [21]. Two studies conducted in Western
Kenya [22] and in rural Zimbabwe [23] found no signifi-
cant difference in praziquantel efficacy in S. mansoni HIV-
1 seronegative or seropositive individuals, in terms of cure
rates or in reduction in intensity of infection, nor was there
any influence of the CD4+ level on the treatment outcome
[22,23].
For over three decades, praziquantel has been the drug
of choice for the treatment and control of the S. man-
soni infection and morbidity [4], but there are concerns
that the parasite may develop resistance against the drug
[24]. Thus, the WHO highly recommends monitoring
praziquantel efficacy in areas with dissimilar levels of S.
mansoni endemicity [25,26] and in infected individuals
of differing immunological statuses [3]. Thus, it remains
important to understand praziquantel efficacy in individ-
uals concurrently infected with HIV-1 and S. mansoni,
and with different immunological statuses (as measured
by CD4+ levels). In the current study, we hypothesisedthat individuals co-infected with HIV-1 and S. mansoni
have lower parasitological cure rates and praziquantel ef-
ficacy depending on their immune status as measured by
CD4+ cell counts. We compared parasitological cure
rates and infection intensity reductions after a single oral
dose of praziquantel was given to HIV-1 seronegative
and seropositive individuals infected with S. mansoni.
Methods
Study population and study area
The study was conducted in the Ilemela District, Mwanza
Region, Northwest Tanzania. The study area is located at
32–34°E and 2–4°S, on the southern shores of Lake
Victoria. Temperature range from 18°C to 28°C and
there is a mean annual rainfall of 1068 mm. Four vil-
lages – Sangabuye, Kayenze, Igalagala and Igombe –
were chosen for their close proximity to the lake. The
majority of the population belongs to the Sukuma tribe.
Other migrant tribes are the Kerewe, Jita and Kara. Most of
the villagers in the four villages depend on the lake for do-
mestic and economic activities. Domestic activities include
washing, bathing, cooking, drinking and recreation, and the
main economic activities are fishing and farming. Due to
high water contact levels, residents have a high risk of being
infected with S. mansoni [27-29], and a high occupational
exposure maintains high intensities of S. mansoni infection
into adulthood [30]. Annual mass drug administration
(MDA) against helminth infections in these villages focuses
on school-age children rather than the adult population.
Moreover, the high rate of sexual mixing within the fishing
villages increases the risk of HIV-1 transmission in the
adult population [31]. In 2003, the HIV-1 prevalence
in individuals aged 15–60 years living in Kayenze and
Sangabuye villages was estimated to be 10% [27].
Study design and sample size
The study consisted of a cross-sectional baseline study
followed by a prospective interventional longitudinal
follow-up. At baseline, the cross-sectional study was
conducted to collect pre-treatment prevalence rates
and intensities of the S. mansoni and HIV-1 infections.
Following this, all infected participants – irrespective of
their HIV-1 serostatus or CD4+ count levels – were
treated with a single dose of praziquantel (40 mg/kg),
and followed up after 12 weeks to assess the efficacy of
the treatment. The study included individuals who had
lived in the study villages for more than two years, ei-
ther male or female, and aged from 21 to 55 years. Indi-
viduals with a history of treatment for schistosomiasis
(praziquantel) in the past six months and those who
were on antiretroviral treatment (ART) were excluded
from the study at the baseline.
To calculate the sample size, we assumed a parasito-
logical cure of 70% in HIV-1 negative individuals infected
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intervals to detect a parasitological cure rate of 60% among
the HIV-1 positive individuals co-infected with S. mansoni,
33 HIV-1 positive individuals and 484 HIV-1 negative indi-
viduals would need to be treated with praziquantel, assum-
ing a loss to follow-up of 10% and a prevalence of HIV
among people infected with schistosomiasis of 6%. This
sample size was estimated using Stata 12 with the com-
mand: sampsi 0.70 0.60, alpha (.95) power (.80) ratio (1.5).
Data collection
(i) HIV-1 screening and CD4+ analysis: All participants
who were involved in the prospective longitudinal
survey and were HIV-1 negative at the baseline
cross-sectional survey were re-tested for the
possibility of HIV-1 seroconversion according to the
Tanzanian national HIV algorithms which use
Determine® (Alere Determine, Chiba, Japan),
followed by UNI-GOLD® (Trinity Biotech PLC,
Bray, Ireland).
(ii) Parasitological examination of the S. mansoni
infection: A single stool sample was obtained, from
which four Kato-Katz thick smears were prepared
[32] using a template of 41.7 mg (Vestergaard
Frandsen, Lausanne, Switzerland). After 24 hours,
the smears were independently examined for S.
mansoni eggs by two experienced technicians from
the National Institute for Medical Research (NIMR)
laboratory. For quality assurance, a random sample
of 10% of the negative and positive Kato-Katz thick
smears were re-examined by a third technician.
(iii)Treatment and follow-up: All 854 individuals found
to be infected with S. mansoni at baseline (aged 21–
55 years), irrespective of their HIV-1 serostatus or
CD4+ cell count levels, were treated with a single
dose of praziquantel (40 mg/kg). These individuals
were followed up and examined for S. mansoni eggs
in their stool samples 12 weeks after treatment.
Data analysis
The data were double entered using CSPro and the final
data set was stored in a MySQL database. The data ana-
lysis was performed using Stata version 12 (StataCorp,
College Station, Texas, USA). The parasitological cure
rates and egg reduction of single-dose praziquantel was
calculated only for individuals who gave single stool
samples at baseline and at the follow-up examination
12 weeks later, from which four Kato Katz thick smears
were prepared. In addition, these individuals received
praziquantel treatment. The S. mansoni egg counts for
each participant were calculated from the average of the
counts from the four Kato-Katz thick smears and multi-
plied by 24 to obtain individuals’ eggs per gram of faeces(epg). To compare the groups, the geometric mean epg
of the S. mansoni infection was obtained as the antilog
of the mean of the transformed log (log epg + 1) egg
counts of individuals in each group. The parasitological
cure rates were calculated as the proportion of individ-
uals who were excreting S. mansoni eggs in their stool
samples prior to praziquantel administration and those
who excreted no eggs after treatment, multiplied by a
factor of 100. Egg count reduction rates were calculated as
[1-(geometric mean epg after treatment/geometric mean
epg before)] multiplied by a factor of 100. The parasito-
logical cure rates were compared between demographic
factors, HIV-1 serostatus; CD4+ cells count levels and the
intensity of the S. mansoni infection. The geometrical
mean epg at baseline and 12 weeks after treatment were
compared with demographic factors, HIV-1 serostatus,
CD4+ cells counts levels and the intensity of the S. mansoni
infection using the t-test or ANOVA. Egg reduction rates
at baseline and 12 weeks after treatment were compared
using the χ2-test or Fisher’s exact test, where appropriate.
The backward elimination logistic model was fitted to de-
termine the factors associated with praziquantel treatment
failure.
Ethical considerations
Ethical approval was obtained from the Higher Degrees
Research and Ethics Committee of the School of Public
Health, Makerere University (IRB-00005856/2011), and
from the joint CUHAS-Bugando Research and Publica-
tions Committee (BREC/001/32/2011). Ethical clearance
was granted by the National Ethical Review Committee,
National Institute for Medical Research, Tanzania, and
the study was registered in the clinical trial network
(Clinical Trial Number NCT-01541631).
The study received further authorisation from the re-
gional and district administrative authorities of the
Mwanza Region and Ilemela District. Swahili-translated
informed assent and consent forms were used to obtain
participants’ consent. For illiterate individuals, a thumb-
print was used to sign the consent forms after a clear de-
scription of the study objectives was given.
All study participants who were infected with S. man-
soni were treated with praziquantel (40 mg/kg) according
to the WHO guidelines, irrespective of their HIV-1 seros-
tatus. The study participants were counselled before and
after HIV testing using the guidelines for HIV testing and
counselling provided by the Ministry of Health and Social
Welfare in Tanzania [33,34]. Trained counsellors, working
with the local district health departments, were involved
in counselling the study participants before the HIV test-
ing was done. All HIV infected individuals were given ac-
cess to CD4+ counting, and those found to have CD4+ <
350 cells/μL were referred to the care and treatment clinic
(CTC) at the nearby health centre and were then referred
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bility for ART and management, according to the guide-
lines of the Ministry of Health and Social Welfare.Results
Parasitological cure rates
Of the 854 individuals found infected at baseline and
treated with praziquantel, 558 (65.33%) were present at
the examination 12 weeks later. Three (3) individuals
experienced HIV-1 seroconversion and were excluded
from the analysis and 299 were absent due to various
reasons, as shown in Figure 1. Pre-treatment parasito-
logical data and demographic information were com-
pared between individuals who were present and absent
at the 12 weeks’ follow-up appointment. There were no
differences in pre-treatment GM-epg between the 555 in-
dividuals who were present (174.21 epg, 95% CI; 154.14–
196.87) and the 299 individuals who were absent (200.92
epg, 95% CI: 167.97–240.34) (t = −1.4012, P = 0.16). Simi-
larly, there were no significant differences in sex distribu-
tion (χ2 = 0.9767, P = 0.32), age distribution (χ2 = 3.1831,Baseline cross-sectional 
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Figure 1 Study profile showing S. mansoni infection among HIV-1 ser
follow-up point.P = 0.36), occupation (χ2 = 0.1168, P = 0.94) and village of
residence (χ2 = 2.6712, P = 0.44).
The 555 individuals infected with S. mansoni at base-
line gave a single stool sample at the 12 weeks’ follow-
up examination. Of these, 526 were HIV-1 negative and
infected with S. mansoni and 29 were co-infected at base-
line. Of the co-infected individuals, 17 had a CD4+ cell
count < 350cells/μL and 12 had a CD4+ count ≥ 350
cells/μL. The overall median CD4+ cell count was 228
cells/μL (range: 202–380).
The overall parasitological cure rate of the entire cohort
was 61.80% (n = 343/555) after 12 weeks. In relation to the
HIV-1 serostatus, among the 526 individuals of the HIV-1
negative cohort infected with S. mansoni at baseline, the
parasitological cure rate was 62.55% (329/526) and, in in-
dividuals who were co-infected with HIV-1 and S. man-
soni, the cure rate was 48.28% (14/29). Parasitological
cure rates did not differ between the HIV-1 serostatus
(P = 0.12). In relation to CD4+ count levels, the parasito-
logical cure rate among HIV-1 and S. mansoni co-infected
individuals with CD4+ cell counts <350 cells/μL was 43.75%
(7/16) and those who had CD4+ cells counts of ≥ 350study 
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logical cure rates did not vary with the CD4+ count
levels (P = 0.23). Table 1 shows the parasitological cure
rates of praziquantel treatment in relation to demo-
graphic factors, HIV-1 serostatus, CD4+ cell count
levels and the intensity of the S. mansoni infection. In
general, the parasitological cure rates did not vary sig-
nificantly in relation to HIV-1 serostatus, CD4+ cells
counts levels and the intensity of the S. mansoni
infection.Table 1 Parasitological cure rate of praziquantel treatment in
levels and S. mansoni infection intensities



























CD4+ count levels (cells/μL)
<350 17
>350 12
S. mansoni infection intensities
Light (1–100 epg) 234
Moderate (101–399 epg) 162
Heavy (≥400 epg) 159
*P-value by chi-square (χ2).Effects of praziquantel treatment on S. mansoni infection
intensities
The overall geometrical mean egg per gram of faeces
(GM-epg) of the entire cohort of 555 individuals at base-
line was 174.21 epg (95% CI: 154.14–196.87) and, after
12 weeks of treatment, the GM-epg was reduced to
39.88 epg (95% CI: 36.77–43.25). The overall egg reduc-
tion rate (ERR) for the entire cohort was 77.11%. In rela-
tion to the HIV-1 serostatus, at baseline, 526 HIV-1
seronegative individuals infected with S. mansoni hadrelation to demographic factors, HIV-1, CD4+ count
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decreased to 39.88 epg (95% CI: 36.69–43.55) in the 212
individuals who remained S. mansoni egg positive. This
translated to an ERR of 77.22% after 12 weeks of treat-
ment. For the co-infected individuals, at baseline, they
had a GM-epg of 159.39 epg (95% CI: 27.20–58.11),
which decreased to 39.85 epg (95% CI: 27.20–58.11) in
the 15 co-infected individuals who remained S. mansoni
egg positive at 12 weeks. This gave an ERR of 75%. TheTable 2 Schistosoma mansoni geometrical mean egg per gram
relation to demographic factors and S. mansoni infection inte
Variable Baseline before treatment
N GM-epg 95% CI
Overall 555 174.21 154.14–196.87
Sex
Female 241 130.36 110.60–153.66
Male 314 217.41 183.01–258.29
Age group
21–30 241 198.67 163.49–241.42
31–40 177 156.18 126.12–193.41
41–50 84 164.09 125.66–214.26
51–60 53 152.13 98.56–234.79
Occupation
Small-scale business 66 136.05 99.65–185.74
Farming 376 157.92 135.73–183.74
Fishing 113 278.74 214.63–362.00
Village of residence
Igombe 112 139.77 109.22–178.86
Igalagala 98 215.61 158.21–293.83
Kayenze 219 197.91 162.96–240.35
Sangabuye 126 144.04 110.22–188.24
Time of residence (years)
3–5 97 188.36 142.36–249.22
6–10 83 156.69 113.85–215.65
11–20 136 204.77 159.53–262.83
≥21 239 159.82 132.07–193.39
HIV-1 serostatus
Negative 526 175.06 154.48–198.39
Positive 29 159.39 86.09–295.14
CD4+ count levels (cells/μL)
<350 17 134.59 52.19–347.07
>350 12 215.78 80.79–576.36
Schistosoma mansoni infection intensities (epg)
Light (1–100 epg) 234 44.43 41.36–47.72
Moderate (101–399 epg 162 199.39 188.32–211.12
Heavy (≥400 epg) 159 1124.33 987.62–1277.36
P-values= t-test* and ANOVA**.overall egg reduction rates did not differ with the HIV-1
serostatus (P = 0.22) (see Table 2). In relation to CD4+
count levels, at baseline, individuals with CD4+ cell
count levels < 350 cell/μL had a GM-epg of 134.59 epg
(95% CI: 52.19–347.07), which decreased to 49.66 epg
(27.16–90.79), giving an ERR of 63.11%. In those who
had CD4+ cell counts ≥ 350 cell/μL at baseline, the GM-epg
was 215.78 epg (80.79–576.36), which decreased to 31.59
epg (95% CI: 13.18–75.69) after 12 weeks of treatment. Forof faeces (GM-epg) after praziquantel treatment in
nsities
12 weeks after treatment
P-values N GM-epg 95% CI P-values
212 39.88 36.77–43.25
0.0001* 119 128.19 99.33–165.43
0.01
93 222.37 168.53–293.41





0.08** 27 35.81 28.97–44.26
0.89**141 39.58 35.71–43.88
44 43.65 36.72-51.88










0.56* 197 39.88 36.69–43.35
0.22*
15 39.85 27.20–58.41







Table 3 Factors associated with praziquantel cure failure
Variable OR 95% CI P-values aOR 95% CI P-values
Sex
Female 1 0.87 1
Male 0.97 0.69–1.37 0.98 0.68–1.39 0.89
Age group
21–30 0.94 0.51–1.73 0.84 0.93 0.50–1.71 0.81
31–40 1.09 0.59–2.05 0.78 1.08 0.58–2.02 0.82
41–50 0.65 0.31–1.33 0.24 0.65 0.31–1.34 0.24
51–60 1 1
Occupation
SME* 1 —— —— ———
Peasants 0.81 0.48–1.38 0.45 —— —— ———
Fishing 0.83 0.45–1.55 0.56 —— —— ———
Village of residence
Igombe 1 —— —— ———
Igalagala 1.21 0.70–2.10 0.49 —— —— ———
Kayenze 0.84 0.53–1.34 0.47 —— —— ———
Sangabuye 0.79 0.47–1.35 0.40 —— —— ———
HIV-1 serostatus
Negative 1 1
Positive 1.79 0.85–3.78 0.13 1.72 0.69–1.39 0.89
CD4+ counts (cells/μL)
<350 1 —— —— ———
≥350 0.38 0.08–1.84 0.23 —— —— ———
S. mansoni intensity of infection
Light 1 —— —— ———
Moderate 0.85 0.56–1.29 0.45 —— —— ———
Heavy 1.06 0.70–1.59 0.79 —— —— ———
*SME-Small business scale, OR = Odd Ratio aOR = Adjusted Odd Ratio.
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with the categories of CD4+ cell counts (P = 0.37). In rela-
tion to demographic factors, a significant ERR was observed
in relation to age groups, with the younger age group
(21–30 years) having an ERR of 81.11% (P < 0.05). Simi-
larly, a significant ERR was observed in relation to the
intensity of the S. mansoni infection (P < 0.0001), with
individuals who had a heavy infection at baseline attain-
ing a ERR of 95.19%. Table 2 shows the comparison of
S. mansoni GM-epg at baseline and at the examination
12 weeks later, after treatment was stratified by demo-
graphic characteristics, HIV-1 serostatus, CD4+ cell count
levels and intensity of the S. mansoni infection.
Factors associated with praziquantel cure failure
Table 3 shows the bivariate and multivariable analysis, il-
lustrating the factors associated with praziquantel cure
failure. Neither at bivariate levels (OR = 1.79, 95% CI:
0.85–3.78, P = 0.13) nor at the multivariable analysis
(aOR = 1.72, 95% CI: 0.69–1.39, P = 0.89) was HIV-1 in-
fection per se associated with praziquantel treatment
failure.
Discussion
In the present study, a relatively small percentage of the
study population was co-infected with HIV-1 and S.
mansoni, resulting in a low to moderate reduction in the
CD4+ cell counts. Praziquantel efficacy, as measured by
parasitological cure rates and reduction in the intensity
of the infection, did not vary significantly with the HIV-1
serostatus and was not influenced by the level of CD4+
cell counts. In relation to the parasitological cure rate
and the reduction in the intensity of infection, individ-
uals co-infected with HIV-1 and S. mansoni responded
to praziquantel treatment the same as HIV-1 seronega-
tive individuals infected with S. mansoni did. Although
co-infected individuals had lower cure rates and reduc-
tion in intensity of infection than the HIV-1 seronegative
individuals infected with S. mansoni, the difference was
not significant. Similarly, praziquantel efficacy – as mea-
sured by parasitological cure rates and the reduction in
intensity of the infection – was not influenced by the
level of CD4+ cell counts. The difference observed in
parasitological cure rates and in reduction in intensity of
infection in the two categories of CD4+ cell counts did
not reach a significant level.
This observed praziquantel efficacy was consistent with
previous studies conducted among humans co-infected
with HIV-1 and S. mansoni [22,23]. In rural Zimbabwe,
the parasitological cure rates assessed 12 weeks after
praziquantel treatment among individuals co-infected with
HIV-1 and S. mansoni infection and those who were only
infected with S. mansoni were 86% and 85%, respectively
[23]. Equally, co-infected individuals and those onlyinfected with S. mansoni experienced similar reductions in
the intensity of the infection [23]. It should be noted that
the Zimbabwean study was conducted in areas with low in-
tensities of the S. mansoni infection [23]; this could partly
explain the very high parasitological cure rates reported
following treatment with a single dose of praziquantel
[8,12,35]. A similar study was conducted in Western
Kenya, in an area highly endemic for S. mansoni infection,
among individuals with a heavy intensity of infection [22].
At four weeks following treatment, a parasitological cure
rate of 59% in the HIV-1 seronegative individuals infected
with S. mansoni and a rate of 53% among co-infected indi-
viduals were observed; an overall egg reduction of 93% was
observed in the two groups [22]. Our study and the one
done by Karanja et al. [22] were conducted among individ-
uals highly infected with S. mansoni, based on egg counts.
This may have in part contributed to the observed low
parasitological cure rates. Previous studies have attributed
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mission of infection and a low sensitivity to praziquantel
among the strains of S. mansoni to low parasitological cure
rates [7].
In the present study, praziquantel efficacy – as mea-
sured by the cure rate and reduced egg excretion – was
not significantly influenced by the level of CD4+ cell
counts, although individuals categorised as having a
lower CD4+ cell count (<350 cells/μL) showed lower
parasitological cure rates and egg excretion. Our obser-
vations were in accordance with studies conducted in
HIV-1 co-infected individuals with low [23] and heavy
intensities of infection [22]. In Western Kenya and rural
Zimbabwe, egg reduction – assessed at four or 12 weeks
after praziquantel treatment – did not differ over a range
of CD4+ cell counts [22]. Our results on praziquantel ef-
ficacy in this population do not mirror those reported
from S. mansoni animal model studies [14,15,17]. In im-
munodeficient mice (nude, T cell depleted and severe
combined immunodeficiency [SCID] mice), charac-
terised by an absence of CD4+ T-lymphocytes and egg
antibodies responses, praziquantel is inefficient in treat-
ing the S. mansoni infection [14,15,17]. However, it is
important to note that the degree of immunosuppres-
sion in the mice used in these model studies was much
greater than the moderate levels of CD4+ reduction
found in the co-infected individuals in the present study.
Interestingly, the passive transfer of serum from infected
immunocompetent mice or from mice immunisation
with S. mansoni worm antigens partly restores the effi-
cacy of praziquantel in severely immunosuppressed mice
[17,19,20], and this is dependent on specific anti-worm
antibodies [19,36].
In schistosomiasis endemic areas, young children are
highly susceptible to infection and re-infection. However,
an acquired partial immunity against infection [37] de-
velops with age, with exposure to adult worms dying over
time or following praziquantel treatment [19,36]. In these
endemic areas, most people will have acquired schistosom-
iasis very early in childhood and will already have had high
levels of anti-worm antibodies by the time they were old
enough to be included in this study. If their anti-worm
antibodies remained high enough, despite the low to mod-
erate reductions in CD4+ T cell counts that resulted from
the HIV-1 infection, it is possible that these antibodies
might contribute to the effective killing of the parasite by
praziquantel, despite the immunosuppressive effects of the
HIV-1 infection. It is likely that the moderate CD4+ T cell
levels observed in co-infected individuals in the present
study were sufficient to support the levels of anti-
schistosome antibodies necessary for an enhanced prazi-
quantel efficacy [19,22,36]. The CD4+ T cell levels that may
be required to ensure an optimum praziquantel efficacy
are not known. This calls for further, more detailed studies.Conclusion
Although this study was limited by the relatively low
percentage of individuals who were co-infected with
schistosomiasis and HIV-1, the results indicate that
HIV-1 infection per se or its moderate immunosuppres-
sive effects, as indicated by the CD4+ T cell counts, does
not significantly affect praziquantel efficacy in terms of
cure rate or reduction in the intensity of infection. This
suggests that, in national schistosomiasis control pro-
grammes, the standard praziquantel dose can be effect-
ive, even deployed in populations where schistosomiasis
and HIV-1 co-infections are likely to occur. This would
also be the case for individual treatment except where
there is an evidence of more severe HIV-1 or AIDS asso-
ciated immunosuppression.
Summary
The present study assessed the efficacy of praziquantel by
comparing parasitological cure rates and the reduction in
infection intensity in HIV-1 seronegative individuals in-
fected with S. mansoni and HIV-1 seropositive individuals
co-infected with S. mansoni, following treatment with a
single oral dose of praziquantel.
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